Develops gene therapy candidates for patients with rare and other serious diseases and licenses global rights to HEMGENIX to CSL Behring.
10-K for FY2025, filed Mar 2, 2026
CSL Behring holds exclusive global rights to HEMGENIX, and Genezen supplies the drug directly to CSL Behring under an arrangement made by uniQure.
10-K for FY2025, filed Mar 2, 2026
No. It lost $199M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$61.2MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
HEMGENIX supply
The older report says uniQure manufactured HEMGENIX for CSL Behring; the latest says Genezen supplies the drug directly to CSL Behring, with uniQure arranging the supply as an agent.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Mar 2, 2026We are a leader in the field of gene therapy and seek to deliver to patients suffering from rare and other devastating diseases single…View ↗
In the period between April 2022 and July 2024, the Company manufactured HEMGENIX for CSL Behring in accordance with a June 2020…View ↗
Pipeline progress
The older report placed temporal lobe epilepsy and Fabry gene therapy candidates in preclinical work; the latest describes clinical candidates for MTLE and Fabry disease.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Mar 2, 2026We are a leader in the field of gene therapy and seek to deliver to patients suffering from rare and other devastating diseases single…View ↗
We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single…View ↗
Competes with Novartis, Roche, Wave Life Sciences, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, Skyhawk Therapeutics, Sarepta Therapeutics, Neurona Therapeutics, EpilepsyGTx, Xenon Pharmaceuticals, Biogen, Ionis Pharmaceuticals, Neurimmune, Coya Therapeutics, Amylyx Pharmaceuticals, NeuroSense Therapeutics, AL-S Pharma, Voyager Therapeutics, Amicus Therapeutics, and Sanofi
10-K for FY2025, filed Mar 2, 2026Our key competitors, focused on developing therapies in various indications, include among others, Novartis, Roche, Wave Life Sciences…View ↗
Loading...